These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 9129932)

  • 21. A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats.
    Tsukamoto S; Akaza H; Onozawa M; Shirai T; Ideyama Y
    Cancer; 1998 Feb; 82(3):531-7. PubMed ID: 9452271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action.
    Furr BJ; Tucker H
    Urology; 1996 Jan; 47(1A Suppl):13-25; discussion 29-32. PubMed ID: 8560673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination treatment versus LHRH alone in advanced prostatic cancer.
    Ferrari P; Castagnetti G; Ferrari G; Baisi B; Dotti A
    Urol Int; 1996; 56 Suppl 1():13-7. PubMed ID: 8776812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The anti-androgen combination, flutamide plus finasteride, paradoxically suppressed LH and androgen concentrations in pregnant spotted hyenas, but not in males.
    Place NJ; Coscia EM; Dahl NJ; Drea CM; Holekamp KE; Roser JF; Sisk CL; Weldele ML; Glickman SE
    Gen Comp Endocrinol; 2011 Feb; 170(3):455-9. PubMed ID: 21036174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate.
    Brufsky A; Fontaine-Rothe P; Berlane K; Rieker P; Jiroutek M; Kaplan I; Kaufman D; Kantoff P
    Urology; 1997 Jun; 49(6):913-20. PubMed ID: 9187700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined finasteride and flutamide therapy in men with advanced prostate cancer.
    Ornstein DK; Rao GS; Johnson B; Charlton ET; Andriole GL
    Urology; 1996 Dec; 48(6):901-5. PubMed ID: 8973674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The effects of LH-RH agonist alone or with flutamide in the treatment of stage D2 prostate cancer].
    Ito T; Aizawa T; Yamamoto S; Ohkubo Y; Tsujino S; Miki M
    Hinyokika Kiyo; 1998 Jul; 44(7):477-80. PubMed ID: 9752601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanism of action and pure antiandrogenic properties of flutamide.
    Labrie F
    Cancer; 1993 Dec; 72(12 Suppl):3816-27. PubMed ID: 8252497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of goserelin and leuprolide in combined androgen blockade therapy.
    Sarosdy MF; Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Vogelzang NJ; Chodak GW; Klein EA; Schellenger JJ; Kolvenbag GJ
    Urology; 1998 Jul; 52(1):82-8. PubMed ID: 9671875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the effects of the 5 alpha-reductase inhibitor finasteride and the antiandrogen flutamide on prostate and genital differentiation: dose-response studies.
    Imperato-McGinley J; Sanchez RS; Spencer JR; Yee B; Vaughan ED
    Endocrinology; 1992 Sep; 131(3):1149-56. PubMed ID: 1324152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of uroplakin expression during urothelial carcinogenesis induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in rats and mice.
    Ogawa K; St John M; Luiza de Oliveira M; Arnold L; Shirai T; Sun TT; Cohen SM
    Toxicol Pathol; 1999; 27(6):645-51. PubMed ID: 10588545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antagonists of growth hormone-releasing hormone (GH-RH) enhance tumour growth inhibition induced by androgen deprivation in human MDA-Pca-2b prostate cancers.
    Letsch M; Schally AV; Stangelberger A; Groot K; Varga JL
    Eur J Cancer; 2004 Feb; 40(3):436-44. PubMed ID: 14746863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy.
    Barqawi AB; Moul JW; Ziada A; Handel L; Crawford ED
    Urology; 2003 Nov; 62(5):872-6. PubMed ID: 14624911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparative study of a gonadotropin-releasing hormone agonist and finasteride on idiopathic hirsutism.
    Bayhan G; Bahçeci M; Demirkol T; Ertem M; Yalinkaya A; Erden AC
    Clin Exp Obstet Gynecol; 2000; 27(3-4):203-6. PubMed ID: 11214952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hormone ablation therapy: lightening the load for today's prostate cancer patient.
    Matthews PA
    Urol Nurs; 2007 Feb; 27 Suppl():3-11. PubMed ID: 17474637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Finasteride plus flutamide for prostatic carcinoma.
    Sandhu SS; Matveev VB; Kaisary AV
    Br J Urol; 1997 Aug; 80(2):360. PubMed ID: 9284230
    [No Abstract]   [Full Text] [Related]  

  • 37. Antiandrogens in combination with LH-RH agonists in prostate cancer.
    Raynaud JP
    Am J Clin Oncol; 1988; 11 Suppl 2():S132-47. PubMed ID: 3071951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of flutamide and finasteride on rat testicular descent.
    Spencer JR; Torrado T; Sanchez RS; Vaughan ED; Imperato-McGinley J
    Endocrinology; 1991 Aug; 129(2):741-8. PubMed ID: 1677329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Total androgen blockade--concept, theory, method and clinical application].
    Ozono S; Hirao Y
    Nihon Rinsho; 1998 Aug; 56(8):2129-34. PubMed ID: 9750521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Local and systemic reduction by topical finasteride or flutamide of hamster flank organ size and enzyme activity.
    Chen C; Puy LA; Simard J; Li X; Singh SM; Labrie F
    J Invest Dermatol; 1995 Nov; 105(5):678-82. PubMed ID: 7594643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.